Expediting hit-to-lead progression in drug discovery through reaction prediction and multi-dimensional optimization
Abstract
Abstract The rapid and economical synthesis of novel bioactive compounds remains a hurdle in drug discovery efforts. This study demonstrates an integrated medicinal chemistry workflow that effectively diversifies hit and lead structures, enabling an acceleration of the critical hit-to-lead optimization phase. Employing high-throughput experimentation (HTE), we generated a comprehensive data set encompassing 13,490 novel Minisci-type C-H alkylation reactions. These data served as the foundation for training deep graph neural networks to accurately predict reaction outcomes. Scaffold-based enumeration of potential Minisci reaction products, starting from moderate inhibitors of monoacylglycerol lipase (MAGL), yielded a virtual library containing 26,375 molecules. This virtual chemical library was evaluated using reaction prediction, physicochemical property assessment, and structure-based scoring, identifying 212 MAGL inhibitor candidates. Of these, 14 compounds were synthesized and exhibited subnanomolar activity, representing a potency improvement of up to 4500 times over the original hit compound. These ligands also showed favorable pharmacological profiles. Co-crystallization of three computationally designed ligands with the MAGL protein provided structural insights into their binding modes. This study demonstrates the potential of combining miniaturized HTE with deep learning and optimization of molecular properties to reduce cycle times in hit-to-lead progression.
Article Details
Authors (24)
David F. Nippa
Kenneth Atz
Yannick Stenzhorn
Alex T. Müller
Andreas Tosstorff
Jörg Benz
Roche Pharma Research & Early Development
Hayley Binch
Markus Bürkler
Achi Haider
Dominik Heer
Roche Pharma Research & Early Development
Remo Hochstrasser
Roche Pharma Research & Early Development
Christian Kramer
Michael Reutlinger
Petra Schneider
Thierry Shema
Andreas Topp
Roche Pharma Research & Early Development
Alexander Walter
Matthias B. Wittwer
Jens Wolfard
Bernd Kuhn
Mario van der Stelt
Division of Drug Discovery and Safety, Leiden Academic Centre for Drug Research
Rainer E. Martin
Uwe Grether
Roche Pharma Research & Early Development
Gisbert Schneider